Oncology

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Jonathan Kolitz
Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute

For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

Download this interview

Similar Interviews

  • Audio Journal of Hematologic Malignancy Special Edition 2005
  • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions, April

  • Audio Journal of Oncology - September 1st, 2006">Audio Journal of Oncology - September 1st, 2006
  • Mark Socinski

  • Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6">Audio Journal of Oncology - June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6
  • Robert Mayer Thierry Facon

    Post a comment

    Subscribe to Audio Medica Podcast